Oppenheimer Initiates Coverage On Precision BioSciences with Outperform Rating, Announces Price Target of $20

Benzinga Newsdesk www.benzinga.com Positive 52.7%

Neg 0% Neu 0% Pos 52.7%

Oppenheimer analyst Joseph Thome initiates coverage on Precision BioSciences (NASDAQ:DTIL) with a Outperform rating and announces Price Target of $20.